Cara Therapeutics (CARA) PT Raised to $33 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cara Therapeutics (CARA) FV Target Raised to $33 at Janney
May 29, 2019 3:40 PM EDTJanney analyst Esther Hong raised the fair value target on Cara Therapeutics (NASDAQ: CARA) to $33.00 (from $27.00) while maintaining a Buy rating following data.
The analyst commented, "Today's announcement of positive Ph.3 KALM-1 IV-Korsuva data demonstrating statistical significance on the primary and all... More
Cara Therapeutics (CARA) PT Raised to $28 at H.C. Wainwright
May 29, 2019 10:55 AM EDTH.C. Wainwright analyst Oren Livnat raised the price target on Cara Therapeutics (NASDAQ: CARA) to $28.00 (from $26.00) while maintaining a Buy rating.
... MoreCara Therapeutics (CARA) PT Raised to $33 at Stifel
May 29, 2019 10:53 AM EDTStifel analyst Annabel Samimy raised the price target on Cara Therapeutics (NASDAQ: CARA) to $33.00 (from $26.00) while maintaining a Buy rating.
... MoreCara Therapeutics (CARA) PT Raised to $35 at Needham & Company
May 29, 2019 10:30 AM EDTNeedham & Company analyst Alan Carr raised the price target on Cara Therapeutics (NASDAQ: CARA) to $35.00 (from $28.00) while maintaining a Buy rating.
Carr commented, "Cara reported today that Korsuva Phase 3 KALM-1 trial met all primary and secondary endpts. Statistically significant and clinically meaningful effects... More
Cara Therapeutics (CARA) option implied volatility comes in after topline data
May 29, 2019 10:01 AM EDTCara Therapeutics (NASDAQ: CARA) June call option implied volatility is at 84, July is at 68; compared to its 52-week range of 47 to 174 after announcing topline data from the KALM-1 pivotal Phase 3 trial of Korsuva Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus.
... MorePre-Open Movers 05/29: (SOLY) (CARA) (AMRN) Higher; (ANF) (GOOS) (CPRI) (more...)
May 29, 2019 9:28 AM EDTToday's Pre-Open Movers
Soliton, Inc. (NASDAQ: SOLY) 53.6% HIGHER; adds to 148% move on Tuesday following FDA 510(k) clearance.
Abercrombie & Fitch (NYSE: ANF) 18.9% LOWER; reported Q1 EPS of ($0.29), $0.15 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $733.97 million versus the consensus estimate of $733.16 million. Q2 Net sales to be flat to up 2%, reflecting an adverse impact from changes in foreign currency exchange rates of approximately $10 million. Q2 Comparable... More
Cara Therapeutics (CARA) option implied volatility elevated into announcing topline data
May 29, 2019 9:23 AM EDTCara Therapeutics (NASDAQ: CARA) June call option implied volatility is at 171, July is at 135; compared to its 52-week range of 47 to 174 into announcing topline data from the KALM-1 pivotal Phase 3 trial of Korsuva Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus.
... MoreStifel Reiterates Buy Rating on Cara Therapeutics (CARA)
May 29, 2019 8:23 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $26.00 price target on Cara Therapeutics (NASDAQ: CARA) following positive top-line data from the first pivotal study (KALM-1) of IV-Korsuva in pruritus associated with chronic kidney disease (CKD-aP) in hemodialysis patients.
The study met its... More
Cara Therapeutics (CARA) to Resume Trading at 7:30 am ET
May 29, 2019 7:04 AM EDTCara Therapeutics (NASDAQ: CARA) to Resume Trading at 7:30 am ET
... MoreCara Therapeutics (CARA) Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus Met Primary Endpoint
May 29, 2019 7:02 AM EDTCara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced positive topline data from the KALM-1 pivotal Phase 3 trial of KORSUVA (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP).
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.000019) Statistically significant improvement in key secondary... More